Søgning
Søgning på udtrykket 'rsv' giver 42 resultater
Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
…er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor. 3) Det er den første originalartikel trykt i den allerførste udgave af et helt nyt HIV-tidsskrift (som formentlig vil blive et betydende tidsskrift på området).
…n (per oralt) blev undersøgt på ca. 700 Vietnamesiske patienter. Men der kunne desværre ikke erkendes nogen forskel i de to grupper. I en leder i samme nummer af NEJM henleder Peter Donald opmærksomheden på de gode behandlingsresultater man har i Cape Town med et kun 6 måneders regime som inkluderer Ethionamid (Trecator), Isoniazid, Rifamipcin og Pyrazinamid. Hvem har herefter opskriften på et nyt, etisk forsvarligt, klinisk studie til behandling af en af de mest alvorlige neuroinfektioner vi kender?
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?
Clinical Infectious Diseases
10.02.2025
Abstract . Background . RSV is an important cause of lower respiratory tract illness (LRTI) in older adults. RSVpreF is a bivalent stabilized prefusion F vaccine containing antigens against RSV-A and RSV-B. In this phase 3 trial in ≥60-year-olds, RSVpreF demonstrated vaccine efficacy (VE) of 88.9% and 77.8% against RSV-associated LRTI with ≥3 symptoms at the end of RSV seasons 1 and 2, respectively. Here we describe final safety and efficacy results and present immunogenicity data.Methods .
Journal of Medical Virology
9.02.2025
Journal of Medical Virology, Volume 97, Issue 2, February 2025.
BMC Infectious Diseases
9.02.2025
. Abstract. . Background. Respiratory syncytial virus (RSV) is an important cause of children’s pulmonary infections. However, there are fewer studies on RSV infections in adults.
BMC Infectious Diseases
8.02.2025
. Abstract. . Background. Respiratory syncytial virus (RSV) is an important cause of children’s pulmonary infections. However, there are fewer studies on RSV infections in adults.
Journal of Infectious Diseases
6.02.2025
Abstract . Introduction . The impact of RSV in older adults is under-recognized, and the limited existing studies on the incidence of hospitalizations show great variability. This study aims to estimate the seasonal incidence rates (IRs) of RSV hospitalizations among adults aged 60 and older (≥60) and evaluate how different case definitions influence these estimates.Methods .
Lancet Respiratory Medicine
5.02.2025
RSV infections in children younger than 5 years in primary care are associated with substantial symptomatology, health-care utilisation, and parental work absence. Notable differences in RSV burden existed across countries, likely due to differences in primary health-care systems, clinical practice, and health-care-seeking behaviour. This study emphasises the importance of considering country-specific primary care burden estimates when considering the implementation of RSV immunisations programmes.
Journal of the American Medical Association
4.02.2025
This prospective study investigates antibody response following respiratory syncytial virus vaccination in immunocompromised individuals.
Journal of Infectious Diseases
3.02.2025
Abstract . RSV can cause severe infections in the elderly. Nirsevimab is a novel prophylactic monoclonal antibody, widely used in infants in France during the 2023/2024 season. It may select for resistant RSV variants that, if transmitted in the community, could compromise vaccine efficacy in the elderly. In this study, we analyzed RSV full-length genomes (68% RSV-A, 32% RSV-B) from 125 patients >60y during 2023/2024 season.
PLoS One Infectious Diseases
13.01.2025
by Jason R. Gantenberg, Kathryn D. Thompson, Robertus van Aalst, David M. Smith, Megan Richards, Christopher B. Nelson, William V. La Via, Sandra S. Chaves, Angela M. Bengtson, David A. Savitz, Andrew R. Zullo . Introduction Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants. Characterizing service utilization during infant RSV hospitalizations may provide important information for prioritizing resources and interventions.
Journal of Infectious Diseases
11.01.2025
Bronchiolitisseverityscorerespiratory syncytial viruspediatricinfants
Nature
10.01.2025
Clinical Infectious Diseases
27.12.2024
Abstract . RSV vaccine clinical trials reported higher frequencies of atrial fibrillation in intervention groups compared to control. In this large, population-based, propensity-matched study, we found RSV vaccine was not associated with increased risk of new-onset or recurrent atrial fibrillation within 1-42 days compared to influenza or Tdap vaccines.
Journal of Infectious Diseases
25.12.2024
Abstract . Background . Socio-economic status (SES) is an important determinant of severe respiratory infections. Despite being a leading cause of hospitalization, limited attention has been given to social inequities in respiratory syncytial virus (RSV), particularly outside of childhood and beyond neighbourhood-level measures. This study aimed to quantify the burden of severe RSV disease across the age continuum by individual-level SES indicators.Methods .
Journal of Infectious Diseases
28.11.2024
Abstract . Background . Clesrovimab is an investigational monoclonal antibody with an extended half-life targeting site IV of the respiratory syncytial virus (RSV) fusion protein for the prevention of RSV disease in infants.Methods . In this phase 1b/2a, double-blind study,183 healthy preterm and full-term infants 2 weeks to 8 months of age were randomized 4:1 within 5 panels (preterm: 20, 50, 75 or 100-mg, full-term: 100 mg) to receive one dose of clesrovimab or placebo.
Journal of Infectious Diseases
28.11.2024
Abstract . Background . Clesrovimab is a human half-life extended mAb in phase 3 evaluation for the prevention of RSV disease in infants. ADA were observed at late time points in a phase 1b/2a study where clesrovimab was well tolerated with an extended half-life of ∼45 days.Methods . Serum samples at days 150, 365 and 545 post-dose were assayed for ADA titers. Samples with high ADA titers were characterized for their binding specificity to the Fab or the YTE portion of clesrovimab.
Lancet Infectious Diseases
26.11.2024
Coadministered mRNA-1345 plus SIIV4 or mRNA-1273.214 vaccines had acceptable safety profiles and elicited mostly non-inferior immune responses compared to individual vaccines in adults aged 50 years or older; only the seroresponse rate difference in nAbs against RSV-A in part A did not meet the non-inferiority criterion. Overall, these data support coadministration of mRNA-1345 with these vaccines in this population; longer-term evaluation continues in this study.
BMJ Open
23.11.2024
. Objectives. To evaluate the cost of delivering childhood respiratory syncytial virus (RSV) prevention interventions to the health system in Kenya. . Design. A prospective (cost projection) activity-based costing study. . Setting. Kenya, national introduction of interventions. . Participants. Not applicable. . Interventions. A single-dose RSV maternal vaccine and a single-dose, long-acting monoclonal antibody (mAb). . Primary and secondary outcome measures.
American Journal of Respiratory and Critical Care Medicine
16.11.2024
American Journal of Respiratory and Critical Care Medicine, Volume 210, Issue 10, Page P7-P8, November 15, 2024.
Journal of Medical Virology
12.11.2024
Journal of Medical Virology, Volume 96, Issue 11, November 2024.
Journal of Infectious Diseases
5.11.2024
Abstract . Background . Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections (ALRIs) associated hospitalisations in children. It is unclear if hospitalized RSV-ALRI differs in clinically from other viral ALRIs. We aimed to compare the disease impact of hospitalised RSV with other viral ALRI in children under 2 years.Methods .
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?
Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season
Eurosurveillance latest updates
14.02.2025
Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77–108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35–50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births. .
Eurosurveillance latest updates
8.02.2025
. Background. Respiratory syncytial virus (RSV) causes substantial morbidity in infants
ProMED
3.02.2025
…ya-news/2515972.html . . . The Center for Disease Control, Ministry of Health, Libya, has. revealed that 70 percent of the current respiratory infections in. Bayda city were due to respiratory virus and 30 percent were due to. influenza virus type B. Of RSV infections, 95 percent were observed in. children, while for influenza B, 50 percent of the cases were in. adults and 50 percent in children. The surveillance team has noted. that all of the infected persons with influenza did not have the.
Medscape Infectious Diseases
22.01.2025
Labels note increased neurologic risk soon after vaccination. . Medscape Medical News
Medscape Infectious Diseases
16.01.2025
Most US states are reporting high or very high flu-like activity, while COVID-19 rates remain lower than this time last year. . WebMD Health News
Medscape Infectious Diseases
8.01.2025
Vaccines and monoclonal antibodies are reducing RSV hospitalizations, but high costs and limited access in low-income countries hinder global epidemiology changes. . Medscape Medical News
Medscape Infectious Diseases
2.01.2025
The RSVpreF vaccine demonstrated 91% effectiveness against RSV-related lower respiratory tract disease in older adults during the first 5 months of use. . Medscape Medical News
Medscape Infectious Diseases
20.12.2024
FDA Committee discussed safety concerns but agreed that more data are needed. . Medscape Medical News
Medscape Infectious Diseases
5.12.2024
Data on real-world effectiveness showed significant benefits in high-risk population. . Medscape Medical News
Medscape Infectious Diseases
26.11.2024
A large study of three databases showed highest hospitalization among older adults with comorbidities. . Medscape Medical News
Medscape Infectious Diseases
22.11.2024
The U.S. Centers for Disease Control and Prevention said on Wednesday it expects to see an increase in levels of COVID-19 and respiratory syncytial virus (RSV) in the. . Reuters Health Information
Medscape Infectious Diseases
29.10.2024
CDC's Jarrett Gartin shares what healthcare providers should know about RSV vaccine recommendations for patients vulnerable to infection. . CDC Expert Commentary
Medscape Infectious Diseases
24.10.2024
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at. . Reuters Health Information
Medscape Infectious Diseases
19.10.2024
(This Oct. 17 story has been corrected to say that the drug reduced some types of respiratory infection, not all, in the headline and paragraphs 1 and 2) . Reuters Health Information
Medscape Infectious Diseases
9.10.2024
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the. . Reuters Health Information
Medscape Infectious Diseases
2.10.2024
The World Health Organization on Tuesday recommended vaccinating pregnant women and administering infants with an antibody to prevent severe respiratory synctial virus (RSV). . Reuters Health Information
Eurosurveillance latest updates
27.09.2024
. Background. Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections and hospitalisations in infants (age 18 years); 7.2% of cases required intensive care unit stay. Mean inpatient medical costs were estimated at EUR 8,046. Most (90.8%) hospitalised infants with RSV were born after 35 weeks of gestation without bronchopulmonary dysplasia or congenital heart disease.
Medscape Infectious Diseases
19.09.2024
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a. . Reuters Health Information
Medscape Infectious Diseases
14.09.2024
Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said. . Medscape Medical News
Medscape Infectious Diseases
16.08.2024
Pfizer said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and. . Reuters Health Information